Literature DB >> 16767366

Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.

Takaki Yoshikawa1, Akira Tsuburaya, Osamu Kobayashi, Motonori Sairenji, Yohei Miyagi.   

Abstract

BACKGROUND: Tissue inhibitor of metalloproteinase-1 (TIMP-1) correlates with tumor progression in patients with gastric cancer; however, the clinical significance of TIMP-1 as a marker for prognosis and recurrence has not been fully clarified.
METHODS: TIMP-1 protein was measured by an enzyme-linked immunosorbent assay in tumor samples from 86 patients who had undergone surgical resection. An intratumoral TIMP-1 value of 10.0 ng/mg protein or more was defined as positive. Patients were followed up for more than 5 years prospectively.
RESULTS: Thirty-one of the 86 patients (36.0%) were positive for TIMP-1. Kaplan-Meier curves for overall survival were significantly different between patients who were positive and those who were negative for TIMP-1. Univariate analysis of factors affecting overall survival showed that depth of tumor invasion; lymph node metastasis; peritoneal dissemination; lymphatic invasion; venous invasion; Lauren classification of histology; curability; and TIMP-1 were statistically significant. Stepwise multivariate analysis for overall survival demonstrated that depth of tumor invasion, nodal metastasis, peritoneal dissemination, and TIMP-1 remained independent prognostic factors. Kaplan-Meier curves for disease-free survival were significantly different between patients who were positive and those who were negative for TIMP-1. The incidence of recurrence was significantly higher in patients positive for TIMP-1 than in those who were negative for TIMP-1. The frequency at each site of recurrence was higher in patients positive for TIMP-1.
CONCLUSION: These results suggested that the protein concentration of TIMP-1 in the tumor extracts was a useful marker for overall survival, disease-free survival, and disease recurrence in patients with gastric cancer. Thus, tumor TIMP-1 may serve to identify a high-risk group, for whom optimal surgical and medical treatment can be given.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16767366     DOI: 10.1007/s10120-006-0362-y

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  41 in total

1.  Cancer incidence in Japan, 1985-89: re-estimation based on data from eight population-based cancer registries. The Research Group for Population-based Cancer Registration in Japan.

Authors: 
Journal:  Jpn J Clin Oncol       Date:  1998-01       Impact factor: 3.019

2.  High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.

Authors:  M N Holten-Andersen; R W Stephens; H J Nielsen; G Murphy; I J Christensen; W Stetler-Stevenson; N Brünner
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

Review 3.  Matrix metalloproteinases in tumour invasion and metastasis.

Authors:  S Curran; G I Murray
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

4.  Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma.

Authors:  M Mori; K Mimori; N Sadanaga; H Inoue; Y Tanaka; K Mafune; H Ueo; G F Barnard
Journal:  Int J Cancer       Date:  2000-11-15       Impact factor: 7.396

5.  Is D2 lymph node dissection necessary for early gastric cancer?

Authors:  Takaki Yoshikawa; Akira Tsuburaya; Osamu Kobayashi; Motonori Sairenji; Hisahiko Motohashi; Yoshikazu Noguchi
Journal:  Ann Surg Oncol       Date:  2002-05       Impact factor: 5.344

6.  Localization and expression of tissue inhibitor of metalloproteinase-1 in human urothelial cancer.

Authors:  Akira Yano; Takahisa Nakamoto; Kunihiro Hashimoto; Tsuguru Usui
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

7.  Matrix metalloproteinases and their inhibitors in gastric cancer.

Authors:  G I Murray; M E Duncan; E Arbuckle; W T Melvin; J E Fothergill
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

Review 8.  Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions.

Authors:  D T Denhardt; B Feng; D R Edwards; E T Cocuzzi; U M Malyankar
Journal:  Pharmacol Ther       Date:  1993-09       Impact factor: 12.310

9.  Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis.

Authors:  Lydia Nakopoulou; Ioanna Giannopoulou; Kalliopi Stefanaki; Effie Panayotopoulou; Ioanna Tsirmpa; Paraskevi Alexandrou; John Mavrommatis; Sophia Katsarou; Panagiotis Davaris
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

10.  TIMP1 and adverse prognosis in non-small cell lung cancer.

Authors:  K M Fong; Y Kida; P V Zimmerman; P J Smith
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

View more
  10 in total

1.  Prognostic value of extracapsular invasion and fibrotic focus in single lymph node metastasis of gastric cancer.

Authors:  Takahide Okamoto; Akira Tsuburaya; Yoichi Kameda; Takaki Yoshikawa; Haruhiko Cho; Kazuhito Tsuchida; Shinichi Hasegawa; Yoshikazu Noguchi
Journal:  Gastric Cancer       Date:  2008-09-30       Impact factor: 7.370

2.  Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer.

Authors:  Takaki Yoshikawa; Haruhiko Cho; Akira Tsuburaya; Osamu Kobayashi
Journal:  Gastric Cancer       Date:  2009-04-24       Impact factor: 7.370

3.  Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.

Authors:  Charlotte Aaberg-Jessen; Karina Christensen; Hanne Offenberg; Annette Bartels; Tanja Dreehsen; Steinbjørn Hansen; Henrik Daa Schrøder; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

4.  Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma.

Authors:  Warner Alpízar-Alpízar; Ole Didrik Laerum; Ib J Christensen; Kjell Ovrebo; Arne Skarstein; Gunilla Høyer-Hansen; Michael Ploug; Martin Illemann
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

5.  Identification of a 6-gene signature predicting prognosis for colorectal cancer.

Authors:  Shuguang Zuo; Gongpeng Dai; Xuequn Ren
Journal:  Cancer Cell Int       Date:  2019-01-05       Impact factor: 5.722

6.  The angiogenic genes predict prognosis and immune characteristics in esophageal squamous cell carcinoma: Evidence from multi-omics and experimental verification.

Authors:  Shuaiyuan Wang; Yinghao Liang; Jiaxin Zhang; Wenjia Wang; Yichen Hong; Miaomiao Sun; Jiao Shu; Kuisheng Chen
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

7.  LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis.

Authors:  Hironobu Shigaki; Yoshifumi Baba; Masayuki Watanabe; Asuka Murata; Shiro Iwagami; Keisuke Miyake; Takatsugu Ishimoto; Masaaki Iwatsuki; Hideo Baba
Journal:  Gastric Cancer       Date:  2012-11-21       Impact factor: 7.370

8.  Expression of the matrix metalloproteases 2, 14, 24, and 25 and tissue inhibitor 3 as potential molecular markers in advanced human gastric cancer.

Authors:  Sol de la Peña; Clara Luz Sampieri; Mariana Ochoa-Lara; Kenneth León-Córdoba; José María Remes-Troche
Journal:  Dis Markers       Date:  2014-02-11       Impact factor: 3.434

9.  Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.

Authors:  Charlotte Aaberg-Jessen; Bo Halle; Stine S Jensen; Sven Müller; Unni Maria Rømer; Christian B Pedersen; Nils Brünner; Bjarne W Kristensen
Journal:  J Neurooncol       Date:  2016-09-12       Impact factor: 4.130

10.  Extranodal soft tissue metastasis as an independent prognostic factor in gastric cancer patients aged under 70 years after curative gastrectomy.

Authors:  Nannan Zhang; Jingyu Deng; Weilin Sun; Yingxin Du; Shiwei Guo; Huihui Bai; Huifang Liu; Han Liang
Journal:  Ann Transl Med       Date:  2020-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.